Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT04947735
Active, not recruiting Not applicable

CYPRESS Efficacy and Safety Study Extension

NCT04947735 · tracked via the Priya Life Science USA tracker
Sponsor
SightGlass Vision, Inc
Phase
Not applicable
Started
2021-07-19
Last updated
2026-05-05

Condition(s) studied

Juvenile MyopiaMyopia

Investigational drug(s) / intervention(s)

Novel spectacle lens designSpectacle lenses

Novel spectacle lens design: Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia

Spectacle lenses: Single vision, impact resistant spectacle lenses

Study summary

This is an open-label, controlled, multisite, two-arm parallel group clinical trial of 36-month duration to evaluate the continued safety and efficacy of SightGlass Vision Diffusion Optics Technology (DOT) Spectacles in reducing the progression of juvenile myopia.

Eligibility

Sex
ALL
Min age
6 Years
Max age
17 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Previously a successfully completed participant in the CYPRESS study (NCT03623074) and having not exited this study for more than 30 days; * Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day); * Willingness to participate in the trial for up to 3 years without contact lens wear; * The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed copy of the form. Exclusion Criteria: * Known allergy to proparacaine, tetracaine, or tropicamide.

Primary outcome measure(s)

  • Axial length — 72 months
    Test vs. control axial length change from baseline
  • Spherical equivalent refraction (SER) — 72 months
    Test vs. control spherical equivalent refraction (SER) change from baseline

Trial sites (12)

FacilityCityRegionStatus
Golden Optometric Group Whittier California
Omega Vision Center, PA Longwood Florida
Kannarr Eye Care Pittsburg Kansas
Haik Humble West Monroe Louisiana
Advanced Eyecare PC Raytown Missouri
SUNY School of Optometry New York New York
Sacco Eye Group Vestal New York
Dunes Eye Consultants Dakota Dunes South Dakota
Total Eye Care Memphis Tennessee
Dr. Bridgitte Shen Lee (PI) Houston Texas
William J Bogus, OD, FAAO Salt Lake City Utah
Centre for Ocular Research and Education Waterloo Ontario

More SightGlass Vision, Inc. trials in the USA

Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses Recruiting
Myopia Control Spectacle Lens Cessation Study Active, not recruiting
Control of Myopia Using Novel Spectacle Lens Designs Active, not recruiting
Spectacle Lens Visual Acuity Assessments Study Active, not recruiting
Children's Viewing Behavior Recruiting

Other trials for the same condition

MiSight 1 Day Safety Post-Approval Study Active, not recruiting
Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses Recruiting
Progressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial Active, not recruiting
Visual Performance of Center Distance Daily Disposable Multifocal Lenses Active, not recruiting
Myopia Control Spectacle Lens Cessation Study Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04947735 on ClinicalTrials.gov ↗ ← All trials in the USA